SCHEMBL6469716

SCHEMBL6469716

COc1cc2nc(Nc3nc(OC(=O)C(F)(F)F)c4cc(OCCN(C)C)ccc4n3)nc(C)c2cc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.37
KDM4E B2RXH2 4/20 0.37
MCHR1 Q99705 2/20 0.37
HSD17B10 Q99714 1/20 0.37
RET P07949 1/20 0.36
TDP2 O95551 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDR P35968 1/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
RAB9A P51151 1/20 0.36
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
MAPT P10636 4/20 0.36
KDM1A O60341 1/20 0.36
EHMT2 Q96KQ7 1/20 0.36
RCOR1 Q9UKL0 1/20 0.36
AURKA O14965 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6469291 0.93 MCHR1 (0.35) ALDH1A1KDM4EMCHR1MEN1KMT2A
SCHEMBL6468701 0.92 CSF1R (0.38) ALDH1A1KDM4ETDP2MEN1KMT2A
SCHEMBL6467974 0.92 KDR (0.38) ALDH1A1KDM4EMEN1KMT2AKDR
SCHEMBL6467450 0.91 FGFR2 (0.40) ALDH1A1KDM4EMCHR1TDP2MEN1
SCHEMBL6467467 0.91 TDP2 (0.38) ALDH1A1KDM4EMCHR1HSD17B10TDP2
SCHEMBL6466266 0.91 RAF1 (0.39) ALDH1A1KDM4ETDP2MEN1KMT2A
SCHEMBL6470212 0.90 TDP2 (0.37) ALDH1A1KDM4EHSD17B10TDP2MEN1
SCHEMBL6465520 0.90 NPSR1 (0.38) ALDH1A1KDM4EHSD17B10TDP2MEN1
SCHEMBL6467169 0.90 MAPT (0.37) ALDH1A1KDM4EHSD17B10TDP2MEN1
SCHEMBL6467359 0.89 FGFR2 (0.37) ALDH1A1KDM4ETDP2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB ALDH1A1 3154/4885KDM4E 3225/4885MCHR1 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.